Key result
NSAIDs appear safe but show no significant LGE benefit over standard therapy in acute myopericarditis.
Why the study?
Clinical data on the effect and safety of NSAIDs in myopericarditis are limited despite their standard use in pericarditis.
Case-Control (n=45)
No
Answers are grounded in this paper and cite their sources.
Supports NSAID safety in acute myopericarditis with preserved LVEF; leaves open LGE benefit in larger trials.
Objective: Clinical data on the effect of non-steroidal anti-inflammatory drugs (NSAIDs) in myopericarditis are limited. Since NSAIDs are standard therapy in pericarditis, we retrospectively investigated their safety in myopericarditis. Methods: In a retrospective case-control study, we identified 60 patients with myopericarditis from September 2010 to August 2017. Diagnosis was based on clinical criteria, elevated high-sensitivity troponin T and cardiac magnetic resonance imaging (CMR). All patients received standard heart failure therapy if indicated. Twenty-nine patients (62%) received NSAIDs (acetylsalicylic acid: n=7, average daily dose =1300 mg or ibuprofen: n=22, average daily dose =1500 mg) for an average duration of 4 weeks. To create two cohorts with similar baseline conditions, 15 patients were excluded. Three months after diagnosis, 29 patients were re-evaluated by CMR to measure late gadolinium enhancement (LGE). Results: Baseline characteristics of those treated with or without NSAIDs were similar. Mean age was 34 (±13) years, 6 (13%) were women. Mean left ventricular ejection fraction (LVEF) was 56% (±5). 82 % of the patients (14 of 17) treated with NSAIDs experienced a decrease in LGE at 3 months, while it was only 58 % (7 of 12) of those without NSAIDs (p=0.15). At 12-month follow-up, one of the patients treated without NSAIDs experienced polymorphic ventricular tachycardia (VT) with cardiac arrest, while one of the patients with NSAIDs experienced non-sustained VT. Conclusions: This is the first case-control study demonstrating that NSAIDs are safe in patients with myopericarditis and preserved LVEF. Our data suggest that this drug class should be tested prospectively in a large randomised clinical trial.
No takes yet. Share an insight, caveat, or question.
Berg et al. (2019) conducted a case-control in Acute myopericarditis (n=45). Non-steroidal anti-inflammatory drugs (NSAIDs) vs. Standard heart failure therapy without NSAIDs was evaluated on Decrease in late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging at 3 months (p=0.15). NSAID use in patients with acute myopericarditis and preserved LVEF was safe over 12 months and showed a non-significant trend toward a greater decrease in late gadolinium enhancement at 3 months compared to standard therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: